Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire New Injectable Medicine Manufacturing Facility of Nexus Pharmaceuticals, Inc. on April 22, 2024. As part of the transaction, Weil, Gotshal & Manges LLP is acting as legal advisor to Eli Lilly and Company. Centerview Partners LLC is acting as financial advisor, and Sullivan & Cromwell LLP as legal advisor to Nexus Pharmaceuticals, Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
770 USD | -0.15% | +1.32% | +32.09% |
May. 17 | Roche: share price stands out, Deutsche Bank in support | CF |
May. 16 | Health Care Flat as Momentum Wanes -- Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B | |
-0.52% | 162B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly and Company entered into a definitive agreement to acquire New Injectable Medicine Manufacturing Facility of Nexus Pharmaceuticals, Inc.